Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.
The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback